Synergistic Effects of BET Inhibitors and Ferroptosis Inducers via Targeted Inhibition of the BRD4/c-Myc/NRF2 Pathway in AML. (PubMed, Eur J Pharmacol) - Apr 20, 2025 - "The combination of BET inhibitors with ferroptosis inducers (RSL3, FIN56, and Erastin) markedly reduced AML cell viability and increased cell death, as demonstrated by CCK-8 assays and flow cytometry analysis across multiple AML cell lines and primary AML patient samples. Finally, survival analyses of AML patients from the TCGA and GSE71014 datasets revealed that elevated expression of BRD4, NRF2, and its downstream target GPX4, an essential ferroptosis regulator, correlated with poor overall survival, highlighting the clinical relevance of our findings. In all, combining BET inhibition with ferroptosis induction could enhance anti-leukemia effect and represent a novel therapeutic strategy for targeting AML cells."
Journal • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • BRD4 • GPX4 • MYC
|
|
Chengwu Zeng; Cunte Chen; Dingrui Nie; Kangjie Qiu; Mengjun Zhong; Quan Yu; Shuxin Zhong; Songnan Sui; Xianfeng Wang; Xin Liu; Xueting Peng; Yangqiu Li; Zhangshuai Dai; Zhi Yu
|